Jul. 14 at 7:55 PM
H.C. Wainwright reiterated
$ABEO Buy-
$20 after
$RARE's CRL for UX111 F/K/A ABO-102 — views
$RARE's UX111 as remaining eminently approvable —
$ABEO would be entitled to royalties on net sales of this candidate if approved — notes that its valuation assessment does not factor in any such royalties and accordingly the CRL does not impact their thesis.
H.C. Wainwright said in its note to investors:
